Safety of protocol violations in acute stroke tPA administration

Journal of Stroke and Cerebrovascular Diseases

Volumn 23, Issue 5, 2014, Pages 855-860

  Lyerly, Michael J ^a,b   Albright, Karen C ^a,c,d   Boehme, Amelia K ^a,c   Bavarsad Shahripour, Reza ^a   Houston, James T ^a   Rawal, Pawan V ^a   Kapoor, Niren ^a   Alvi, Muhammad ^a   Sisson, April ^a   Alexandrov, Anne W ^a,c   Alexandrov, Andrei V ^a  

^a The University of Alabama at Birmingham   (United States)

^b BIRMINGHAM VA MEDICAL CENTER   (United States)

^c UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^d UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

Author keywords

Acute ischemic stroke; patient safety; protocol violation; symptomatic intracerebral hemorrhage; thrombolysis

Indexed keywords

GLUCOSE; TISSUE PLASMINOGEN ACTIVATOR; ANTIHYPERTENSIVE AGENT; FIBRINOLYTIC AGENT;

ADULT; AGED; ARTICLE; BLOOD CLOT LYSIS; BRAIN HEMORRHAGE; CEREBROVASCULAR ACCIDENT; CLINICAL PROTOCOL; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; NATIONAL INSTITUTES OF HEALTH STROKE SCALE; PARTIAL THROMBOPLASTIN TIME; PATIENT SAFETY; PRIORITY JOURNAL; PROTHROMBIN TIME; PROTOCOL COMPLIANCE; RANKIN SCALE; BLEEDING; BLOOD CLOTTING TEST; CHEMICALLY INDUCED; CHI SQUARE DISTRIBUTION; CLINICAL PRACTICE; CROSS-SECTIONAL STUDY; FIBRINOLYTIC THERAPY; HOSPITAL ADMISSION; MIDDLE AGED; PATIENT SELECTION; PRACTICE GUIDELINE; REGISTER; RETROSPECTIVE STUDY; RISK; RISK ASSESSMENT; RISK FACTOR; STANDARDS; STATISTICAL MODEL; TIME TO TREATMENT; TREATMENT OUTCOME; UNITED STATES; VERY ELDERLY; YOUNG ADULT;

ADULT; AGED; AGED, 80 AND OVER; ALABAMA; ANTIHYPERTENSIVE AGENTS; BLOOD COAGULATION TESTS; CHI-SQUARE DISTRIBUTION; CROSS-SECTIONAL STUDIES; FEMALE; FIBRINOLYTIC AGENTS; GUIDELINE ADHERENCE; HEMORRHAGE; HUMANS; LOGISTIC MODELS; MALE; MIDDLE AGED; ODDS RATIO; OUTCOME AND PROCESS ASSESSMENT (HEALTH CARE); PATIENT ADMISSION; PATIENT SAFETY; PATIENT SELECTION; PHYSICIAN'S PRACTICE PATTERNS; PRACTICE GUIDELINES AS TOPIC; REGISTRIES; RETROSPECTIVE STUDIES; RISK ASSESSMENT; RISK FACTORS; THROMBOLYTIC THERAPY; TIME-TO-TREATMENT; TISSUE PLASMINOGEN ACTIVATOR; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84901307296     PISSN: 10523057     EISSN: 15328511     Source Type: Journal    
DOI: 10.1016/j.jstrokecerebrovasdis.2013.07.019     Document Type: Article

References (25)

1. V.L. Roger, A.S. Go, and D.M. Lloyd-Jones et al. Heart disease and stroke statistics - 2012 update: a report from the American Heart Association Circulation 125 2012 e2 e220
2. Tissue plasminogen activator for acute ischemic stroke. The National Institute of Neurological Disorders and Stroke rt-pa Stroke Study Group N Engl J Med 333 1995 1581 1587
3. D. Kleindorfer, C.J. Lindsell, and L. Brass et al. National US estimates of recombinant tissue plasminogen activator use: ICD-9 codes substantially underestimate Stroke 39 2008 924 928
4. M.J. Reeves, S. Arora, and J.P. Broderick et al. Acute stroke care in the US: results from 4 pilot prototypes of the Paul Coverdell National Acute Stroke Registry Stroke 36 2005 1232 1240
5. K.Z. Bambauer, S.C. Johnston, and D.E. Bambauer et al. Reasons why few patients with acute stroke receive tissue plasminogen activator Arch Neurol 63 2006 661 664
6. L.S. Williams, A. Bruno, and D. Rouch et al. Stroke patients' knowledge of stroke. Influence on time to presentation Stroke 28 1997 912 915
7. D.L. Brown, W.G. Barsan, and L.D. Lisabeth et al. Survey of emergency physicians about recombinant tissue plasminogen activator for acute ischemic stroke Ann Emerg Med 46 2005 56 60
8. M. Guillan, A. Alonso-Canovas, and J. Garcia-Caldentey et al. Off-label intravenous thrombolysis in acute stroke Eur J Neurol 19 2012 390 394
9. C.E. Kvistad, N. Logallo, and L. Thomassen et al. Safety of off-label stroke treatment with tissue plasminogen activator Acta Neurolog Scand 128 2013 48 53
10. L. Breuer, C. Blinzler, and H.B. Huttner et al. Off-label thrombolysis for acute ischemic stroke: rate, clinical outcome and safety are influenced by the definition of 'minor stroke' Cerebrovasc Dis 32 2011 177 185
11. A. Meretoja, J. Putaala, and T. Tatlisumak et al. Off-label thrombolysis is not associated with poor outcome in patients with stroke Stroke 41 2010 1450 1458
12. A. Aleu, P. Mellado, and C. Lichy et al. Hemorrhagic complications after off-label thrombolysis for ischemic stroke Stroke 38 2007 417 422
13. W.T. Longstreth Jr., R. Katz, and D.L. Tirschwell et al. Intravenous tissue plasminogen activator and stroke in the elderly Am J Emerg Med 28 2010 359 363
14. N. Wahlgren, N. Ahmed, and A. Davalos et al. Thrombolysis with alteplase for acute ischaemic stroke in the safe implementation of thrombolysis in stroke-monitoring study (SITS-MOST): an observational study Lancet 369 2007 275 282
15. R. Bender, and S. Lange Adjusting for multiple testing - when and how? J Clin Epidemiol 54 2001 343 349
16. W. Hacke, M. Kaste, and E. Bluhmki et al. Thrombolysis with alteplase 3 to 4.5 hours after acute ischemic stroke N Engl J Med 359 2008 1317 1329
17. N. Wahlgren, N. Ahmed, and A. Davalos et al. Thrombolysis with alteplase 3-4.5 h after acute ischaemic stroke (SITS-ISTR): an observational study Lancet 372 2008 1303 1309
18. S. Martin-Schild, H. Hallevi, and K.C. Albright et al. Aggressive blood pressure-lowering treatment before intravenous tissue plasminogen activator therapy in acute ischemic stroke Arch Neurol 65 2008 1174 1178
19. N.L. Ifejika-Jones, N. Harun, and N.A. Mohammed-Rajput et al. Thrombolysis with intravenous tissue plasminogen activator predicts a favorable discharge disposition in patients with acute ischemic stroke Stroke 42 2011 700 704
20. C.I. Chen, Y. Iguchi, and J.C. Grotta et al. Intravenous tPa for very old stroke patients Eur Neurol 54 2005 140 144
21. J. Berrouschot, J. Rother, and J. Glahn et al. Outcome and severe hemorrhagic complications of intravenous thrombolysis with tissue plasminogen activator in very old (≥80 years) stroke patients Stroke 36 2005 2421 2425
22. P.N. Sylaja, R. Cote, A.M. Buchan Canadian Alteplase for Stroke Effectiveness Study I Thrombolysis in patients older than 80 years with acute ischaemic stroke: Canadian alteplase for stroke effectiveness study J Neurol Neurosurg Psychiatry 77 2006 826 829
23. ISTc Group P. Sandercock, and J.M. Wardlaw et al. The benefits and harms of intravenous thrombolysis with recombinant tissue plasminogen activator within 6 h of acute ischaemic stroke (The Third International Stroke Trial [IST-3]): a randomised controlled trial Lancet 379 2012 2352 2363
24. M. Karlinski, A. Kobayashi, and R. Mikulik et al. Intravenous alteplase in ischemic stroke patients not fully adhering to the current drug license in central and Eastern Europe Int J Stroke 7 2012 615 622
25. B. Ovbiagele, and J.L. Saver Day-90 acute ischemic stroke outcomes can be derived from early functional activity level Cerebrovasc Dis 29 2010 50 56